Clinical Trial Update: Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating combretastatin with paclitaxel and carboplatin for anaplastic thyroid carcinoma was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Combretastatin (combretastatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Mateon Therapeutics | Conditions: Anaplastic Thyroid Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2014-06-09